Department of Dermatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Immunotherapy. 2022 Oct;14(14):1149-1164. doi: 10.2217/imt-2022-0054. Epub 2022 Aug 31.
In the past decade, the emergence of biologics targeting human cytokine networks has advanced a new era in atopic dermatitis therapy. Dupilumab, in particular, the most widely studied and used IL-4/IL-13 inhibitor, has been considered a milestone in the treatment of patients with moderate-to-severe atopic dermatitis. In addition to the IL-4 and IL-13 pathways, many other cytokines and receptors have been newly targeted as therapeutic options. In this review, the authors provide an overview of the approved and tested biologics and JAK inhibitors for the treatment of atopic dermatitis, including their advantages and limitations.
在过去的十年中，针对人类细胞因子网络的生物制剂的出现推动了特应性皮炎治疗的新时代。特别是 Dupilumab，研究和使用最广泛的 IL-4/IL-13 抑制剂，被认为是治疗中重度特应性皮炎患者的一个里程碑。除了 IL-4 和 IL-13 途径外，许多其他细胞因子和受体已被新定为治疗选择。在这篇综述中，作者概述了已批准和正在测试的用于治疗特应性皮炎的生物制剂和 JAK 抑制剂，包括它们的优点和局限性。
